Akari Therapeutics, Plc (NASDAQ: AKTX) released a new CEO Corner segment on Aug. 04, 2026, highlighting a strategic research collaboration with WhiteHawk Therapeutics aimed at advancing next-generation antibody drug conjugates (ADCs). President and Chief Executive Officer Abizer Gaslightwala discussed how the partnership combines Akari’s proprietary PH1 spliceosome-modulating payload with WhiteHawk’s differentiated TOP1 inhibitor ADC platform to evaluate a novel dual-payload strategy. This move signals a shift in the oncology biotechnology landscape toward collaborative strategies that combine complementary mechanisms of action to unlock new therapeutic opportunities.

The collaboration focuses on integrating two potentially best-in-class payload technologies to broaden therapeutic activity while reinforcing the versatility of Akari’s PH1 platform. Gaslightwala explained that bringing together differentiated scientific approaches has the potential to accelerate innovation and generate meaningful translational insights that may not be achievable through a single technology alone. The company views such scientifically driven collaborations as increasingly important for advancing ADC innovation and addressing unmet needs across oncology.

Strategic Rationale for Dual-Payload Approach

At the center of the discussion is the belief that the ADC landscape is evolving beyond individual payload technologies. By combining Akari’s PH1 payload, which targets RNA splicing, with WhiteHawk’s TOP1 inhibitor, the companies aim to create a synergistic effect in tumor cell killing. Gaslightwala noted that this approach allows for additional opportunities to expand the scientific validation of novel payload platforms while creating new pathways for innovation through partnerships with organizations sharing a common vision for advancing ADC science.

Pipeline Progress and Future Outlook

Beyond the collaboration, Gaslightwala outlined Akari’s continued focus on advancing its lead candidate, AKTX-101, toward planned Phase 1 clinical evaluation. AKTX-101 is a TROP2-targeting ADC designed to deliver the PH1 payload directly into tumors with minimal off-target effects. The company has initiated IND-enabling studies for AKTX-101 with a goal of starting its First-In-Human trial by mid-2027. Preclinical studies have shown significant activity and prolonged survival relative to ADCs with traditional payloads, with potential synergy with checkpoint inhibitors.

Akari is also developing AKTX-102, an ADC candidate targeting CEACAM5, which leverages the PH1 payload and a novel antibody construct for differentiated tumor cell killing. Gaslightwala emphasized that internal development programs and strategic collaborations represent complementary components of a broader strategy to establish PH1 as a differentiated payload platform supporting multiple future therapeutic applications. The PH1 payload has demonstrated activity against cancer cells with key oncogenic drivers such as KRAS, BRAF, ARV7, and FGFR3 fusions.

What the Numbers Show

While no financial metrics were disclosed in this communication, the strategic pivot toward dual-payload collaborations indicates a focus on de-risking clinical development through scientific validation rather than standalone asset progression. The timeline for AKTX-101’s First-In-Human trial by mid-2027 remains a critical near-term milestone for investors monitoring capital efficiency and pipeline velocity.

Akari Therapeutics, Plc has entered a strategic research collaboration with Whitehawk Therapeutics to evaluate the potential of combining Akari's proprietary PH1 spliceosome-modulating payload technology with Whitehawk's topoisomerase I inhibitor (TOP1i) antibody drug conjugate (ADC) platform. The partnership aims to advance ADC innovation by assessing dual payload compatibility and synergies through a series of focused preclinical studies. Abizer Gaslightwala, Director, President and Chief Executive Officer of Akari Therapeutics, highlighted the increasing industry focus on differentiated ADC payload technologies, noting that recent strategic transactions continue to underscore the growing value being placed on novel payload innovation.

Under the agreement, Akari will lead the design, execution, and evaluation of the research activities. The initial collaboration includes multiple preclinical workstreams intended to generate data that will guide future development decisions and potentially broader collaboration opportunities between the two companies. The planned preclinical studies are designed to assess dual payload synergy and generate data that could support future development opportunities for next generation ADCs.

Collaboration Objectives

The primary goal of the collaboration is to explore the broader potential of Akari's PH1 payload technology to combine with current classes of ADC payloads. The studies are designed to validate PH1's differentiated mechanism and support the development of a first-in-class dual payload technology for novel ADCs targeting cancer. The discussion also explored the scientific rationale for combining differentiated ADC payload technologies, how dual payload approaches may expand therapeutic opportunities beyond traditional single payload ADCs, and why management believes collaborations such as Whitehawk further validate the broad applicability of Akari's PH1 platform across future oncology programs.

Executive Perspectives

Abizer Gaslightwala, Director, President and Chief Executive Officer of Akari Therapeutics, emphasized the significance of the collaboration. "This collaboration marks an important first step in exploring the broader potential of our PH1 payload technology to combine in unique ways with current classes of ADC payloads across the field to advance ADC innovation and impact," he stated. "As the ADC field continues to evolve and industry interest shifts toward differentiated payload innovation, we believe Akari is uniquely positioned to help shape the next generation of ADCs through our novel spliceosome modulating platform and strategic collaborations such as this one."

Dave Lennon, PhD, President and Chief Executive Officer of Whitehawk Therapeutics, highlighted the strategic fit. "Beyond our existing portfolio, we see dual-payload approaches as a potential next opportunity to expand the therapeutic potential of our ADC platform," Lennon said.

Key Technologies

The collaboration is expected to commence immediately, with interim data updates anticipated as studies progress. Both companies will jointly review the resulting data to determine whether the findings support broader development discussions.